Small-Molecule Drug Services

Up to now, small molecule drugs involved in therapeutic use can be divided into small molecule inhibitors, small molecule antagonists, small molecule agonists and small molecule activators. They are also valuable ...

Small molecules predominantly modulate the activity of their protein targets. The majority of approved small molecule inhibitors target intracellular kinases, which regulate cell signaling by transferring phosphate groups to target proteins. ...

Simple : CarbonAI searches over 1.9 billion compounds to create synthesizable drug candidates – based only on target sequence. Precise : CarbonAI accurately identifies the most active and safe compound with a multi-objective optimization ...

Kinases, in simple terms, are enzymes that transfer the phosphate groups of ATP to substrates. Kinases catalyze the transfer of γ-phosphate groups of ATP to substrates, mediate most signal transduction, and regulate a variety of cellular activities, including proliferation, survival, apoptosis, metabolism, transcription, differentiation, and a wide range of other cellular processes. ...

Receptors are biomolecules that can bind with hormones, neurotransmitters, drugs, or intracellular signaling molecules and are capable of inducing changes in cellular function. Receptors are categorized based on their cellular location into cell surface receptors and intracellular receptors. Each receptor typically has two active sites: one that recognizes and ...

Therefore, the identification of the target protein of small molecule drug action is crucial for understanding the mechanism of action and application of small molecule drugs, and can also further discover the ...

One-Stop Solution for Small Molecule Drug Formulation: Small molecule drugs are chemically synthesized small molecules of active substances. Small molecule components can be made into tablets or capsules that are easily absorbed ...

Ion channels are made up of special proteins produced by cells, which are aggregated and embedded in the cell membrane, forming pores occupied by water molecules. These pores are the channels for water-soluble substances, which can quickly enter and exit the ...

One of the challenges in drug discovery and development is miniaturization. Miniaturization is key to automating small molecule discovery, facilitating higher throughput, increasing reliability and accuracy and reducing costs for screening large compound libraries. ...

Strateos offers a wide range of the shelf assays and supports custom development of biochemical, biophysical and cellular assays using both industry-standard and innovative technologies to support drug discovery projects from hit identification to lead optimization. We also have broad experience in a variety of target classes ranging from GPCRs, kinases, ion channels, nuclear ...

Miniaturization is key to facilitating higher throughput, increasing reliability and accuracy and reducing costs for screening large compound libraries. We have a solid track record in miniaturizing challenging assays to 384- and 1536-well formats for medium to Ultra-High-Throughput Screening (uHTS). Strateos’ smart labs collectively span over 14K sqft and are composed of automated ...

Hit discovery or hit identification in drug development is driven by the need to identify small molecules with desirable activity in a compound screen against a target. Our state-of-the-art fully automated robotic platform is set-up to accelerate your drug discovery process starting with robust, targeted hit identification ...

High throughput screening (HTS) in drug discovery is critical for drug discovery and is a widely used tool for querying small molecule chemical libraries to determine the structure-activity relationship (SAR) of molecules and helps drive the development of specific and potent bioactive ...

Crystalsfirst Unlocks Chemical Matter On Scale By Putting Structural Data First. We have developed technologies that overcome current limitations of small molecule drug discovery. The integration of our high-performance structural biology, compound libraries with computational chemistry capabilities identifies novel molecules and ...

We provide rapid and comprehensive support for your early-phase drug development process, enabling you to establish 'critical mass' – in terms of personnel and know-how – in the chemical and analytical development of complex small-molecule ...

Protein-based macromolecular drugs, typically organic compounds with molecular weights exceeding 1000, depend on cellular biosynthesis and are also known as biologics. Compared to traditional small molecule drugs, protein drugs are characterized by their high potency, strong specificity, low toxicity, clear ...

Peptides are compounds formed by multiple amino acids linked by peptide bonds and can be prepared via recombinant DNA expression, biological extraction, or chemical synthesis. Peptides represent a unique class of drugs with certain characteristics of small molecule drugs as well as properties of large proteins and other ...

Macromolecules play an integral role in therapeutic research and development, encompassing therapeutic drugs such as monoclonal antibodies, recombinant proteins, polypeptides, antibody-drug conjugates (ADCs), and bispecific antibodies. Unlike small molecule drugs that are less than 1kDa, macromolecules have a ...

Drug affinity responsive target stability is a label-free small molecule probe technique under chemical proteomics first proposed by Lomenick et al. in 2009, which makes it possible to track and identify target proteins whose stability changes after binding with small molecules. ...

Finding rare events: The Lightcast platform is designed to have a high throughput and will be ideally suited to finding one in 10,000 or one in 100,000 ...